Inventiva (NASDAQ:IVA) Shares Gap Up - Here's Why

Key Points

• Shares of Inventiva gapped up, opening at $5.18 versus a $4.97 close and trading around $5.125 (up ~3.6%) on volume of about 16,606 shares.
• Analyst views are mixed but the consensus is a Buy with an average price target of $16.56; notable initiations include UBS (Buy, $12 PT) and Barclays (Overweight, $18 PT), while some firms (Wall Street Zen, Weiss) rate it a sell.
• Inventiva is a clinical‑stage biopharma whose lead asset, lanifibranor (IVA337), is in Phase III for NASH, though the company reported a quarterly loss (‑$0.16 EPS) and minimal revenue, with analysts forecasting roughly ‑1.17 EPS for the year; institutional investors recently added large positions and own about 19% of the stock.

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $4.97, but opened at $5.18. Inventiva shares last traded at $5.1250, with a volume of 16,606 shares changing hands.

Analyst Ratings Changes

Several equities analysts have recently issued reports on IVA shares. Wall Street Zen lowered Inventiva from a "hold" rating to a "sell" rating in a research note on Saturday, April 11th. UBS Group started coverage on Inventiva in a research note on Wednesday, January 7th. They issued a "buy" rating and a $12.00 price target on the stock. Barclays started coverage on Inventiva in a research note on Tuesday, January 27th. They issued an "overweight" rating and a $18.00 price target on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Inventiva in a research note on Tuesday, April 21st. Finally, Leerink Partners started coverage on Inventiva in a research note on Monday, January 12th. They issued an "outperform" rating and a $12.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Inventiva currently has a consensus rating of "Buy" and an average price target of $16.56.

Inventiva Trading Up 3.6%

The company has a fifty day moving average of $5.83 and a two-hundred day moving average of $5.33.

Inventiva (NASDAQ:IVA - Get Free Report) last released its quarterly earnings data on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The company had revenue of $0.01 million during the quarter. Research analysts forecast that Inventiva S.A. Sponsored ADR will post -1.17 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of IVA. Paradigm Biocapital Advisors LP bought a new position in Inventiva during the 4th quarter worth $18,600,000. ADAR1 Capital Management LLC bought a new position in Inventiva during the 4th quarter worth $12,601,000. UBS Group AG raised its position in Inventiva by 28,881.6% during the 4th quarter. UBS Group AG now owns 2,643,702 shares of the company's stock worth $12,293,000 after purchasing an additional 2,634,580 shares during the last quarter. SymBiosis Capital Partners LLC bought a new position in Inventiva during the 4th quarter worth $12,090,000. Finally, Millennium Management LLC raised its position in Inventiva by 2,267.7% during the 4th quarter. Millennium Management LLC now owns 2,652,570 shares of the company's stock worth $12,334,000 after purchasing an additional 2,540,540 shares during the last quarter. 19.06% of the stock is owned by institutional investors.

About Inventiva

Inventiva NASDAQ: IVA is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company's core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva's scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company's lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.